Keytruda (pembrolizumab), a leading anti-PD-1 immuno-oncology drug, is making history in the treatment of lung cancer by expanding beyond the treatment of stage 4 non-small cell lung cancer (NSCLC) and redefining the concept of adjuvant, or "perioperative," therapy in patients with early-stag...
Tumors can be benign or malignant; when we speak of "cancer," we are referring to malignant tumors. Medical professionals can usually remove benign tumors, and these tumors do not spread to other parts of the body. Malignant tumors, on the other hand, often grow aggressively locally where th...
Tumors can be benign or malignant; when we speak of "cancer," we are referring to malignant tumors. Medical professionals can usually remove benign tumors, and these tumors do not spread to other parts of the body. Malignant tumors, on the other hand, often grow aggressively locally where th...
Drug Shows Early Promise for Advanced Lung Cancer; Keytruda Is Already Approved to Treat MelanomaNorton, Amy
KEYTRUDA may be used alone as your first treatment when your lung cancer has not spread outside your chest (stage III) and you cannot have surgery or chemotherapy with radiation, or your NSCLC has spread to other areas of your body (advanced NSCLC), and your tumor tests positive for “PD...
Merck & Co’s PD-1 inhibitor Keytruda has added a new indication in Europe, getting a green light for use in non-small cell lung cancer (NSCLC) patients. The European Commission has approvedKeytruda(pembrolizumab) for second-line treatment after chemotherapy of patients with locally advanced or...
preventing an immune evasion mechanism involving the interaction between PD-L1 in cancer cells and thePD-1receptor in T-cells, immune cells involved in the fight against cancer. Tumors with high levels of PD-L1 (more than 50% of cells producing PD-L1) tend to ...
Merck's Keytruda shines in lung cancer study Impressive data from a large clinical trial of Merck & Co.'s immunotherapy Keytruda herald a new approach to treating certain kinds of lung cancer. The results were reported last week at the American Association for Cancer Research (AACR... L ...
Surgery, which is generally used forstage 1,stage 2, and somestage 3cancers Chemotherapydestroys cancer cells Radiation therapyis used before or after surgery or chemotherapy to shrink the tumor Immunotherapyincludes drugs like Opdivo (nivolumab) or Keytruda (pembrolizumab) to stimulate a defensive imm...
Merck and the European Thoracic Oncology Platform (ETOP) recently announced that Keytruda significantly improved disease-free survival (DFS) in patients with stage IB to IIA non-small cell lung cancer (NSCLC) in a Phase 3 clinical trial.